Evidence map›Paper›PMID 31280390›Full record

ArticleDigestive diseases and sciences2019

In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue.

Lung-Yi Mak, Sze-Hang Liu, Desmond Yat-Hin Yap, Wai-Kay Seto, Danny Ka-Ho Wong, James Fung, Tak-Mao Chan, Ching-Lung Lai, Man-Fung Yuen

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03778567 (The Effect of Telbivudine on Renal Function in Chronic Hepatitis B Patients With Mild to Moderate Renal Impairment), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03778567 phase4completednot on this map

The Effect of Telbivudine on Renal Function in Chronic Hepatitis B Patients With Mild to Moderate Renal Impairment

TypeinterventionalSponsorThe University of Hong KongRan2013 to 2018Enrolled31ConditionsHepatitis B, Chronic, Chronic Kidney DiseasesArmsTelbivudine
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Lung-Yi Mak *Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Pokfulam, Hong Kong.
Sze-Hang Liu *Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Pokfulam, Hong Kong.
Desmond Yat-Hin YapDepartment of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Pokfulam, Hong Kong.
Wai-Kay SetoDepartment of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Pokfulam, Hong Kong.
Danny Ka-Ho WongDepartment of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Pokfulam, Hong Kong.
James FungDepartment of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Pokfulam, Hong Kong.
Tak-Mao ChanDepartment of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Pokfulam, Hong Kong.
Ching-Lung LaiDepartment of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Pokfulam, Hong Kong.
Man-Fung YuenDepartment of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Pokfulam, Hong Kong. mfyuen@hkucc.hku.hk.
University of Hong Kong · HKQueen Mary Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimRenal toxicity of adefovir disoproxil (ADV) and tenofovir disoproxil fumarate (TDF) is a significant concern in chronic hepatitis B (CHB) patients. Early observational clinical data suggested that telbivudine (LdT) might have renoprotective effects.

methodsIn this prospective study, consecutive CHB patients on combined lamivudine (LAM) + ADV/TDF were switched to LdT + ADV/TDF at recruitment and were followed up for 24 months. Estimated glomerular filtration rate (eGFR) was calculated with the modification of diet in renal disease equation. The effects of LdT on cell viability and expression of kidney injury or apoptotic biomarkers were investigated in cultured renal tubular epithelial cell line HK-2.

resultsThirty-one patients (median age 55 years, 90.3% male) were recruited (54.8% TDF: 45.2% ADV). Serum HBV DNA was undetectable at all time points. Median eGFR was 70.2 (IQR 62.6-77.9) and 81.5 (IQR 63.6-99.1) mL/min/1.73 m

conclusionsClinical and in vitro data suggest that LdT has renoprotective effects in patients on long-term ADV/TDF treatment. LdT may be considered as an adjuvant therapy in this special group of patients with renal impairment (NCT03778567).

Indexed as

Glomerular Filtration RateActivating Transcription Factor 4AdenineAntiviral AgentsApoptosisCaspase 12Cell LineCell SurvivalEndoplasmic Reticulum Chaperone BiPEpithelial CellsFemaleHeat-Shock ProteinsHepatitis A Virus Cellular Receptor 1Hepatitis B, ChronicHumansInterleukin-18Activating Transcription Factor 4adefovir dipivoxilAdenineAntiviral AgentsATF4 protein, humanCASP12 protein, humanCaspase 12Endoplasmic Reticulum Chaperone BiPHAVCR1 protein, humanHeat-Shock ProteinsHepatitis A Virus Cellular Receptor 1Interleukin-18LamivudineLCN2 protein, humanLipocalin-2OrganophosphonatesProtective AgentsTelbivudineTenofovirAntiviralHBVNephrotoxicityNucleoside analoguesTenofovir

Identifiers

PMID31280390
OpenAlexW2953698230

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.